Previous 10 | Next 10 |
Syndax Pharmaceuticals (NASDAQ: SNDX ): Q4 GAAP EPS of -$0.70 misses by $0.01 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WALTHAM, Mass. , March 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ...
WALTHAM, Mass. , March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison , M.D., Chief Executive O...
WALTHAM, Mass. , Feb. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2018 ...
WALTHAM, Mass. , Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American As...
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc. (NASDAQ:CRON), Spectrum Brands Holdings Inc. (NYSE:S...
Syndax Pharmaceuticals (NASDAQ: SNDX ) provided a 2019 clinical and corporate outlook. More news on: Syndax Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
WALTHAM, Mass. , Jan. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today provided a 2019 clinical and corporate outlook. "2019...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2018 Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Melissa Forst - Argot Partners, VP Briggs Morrison - CEO Michael Metzger - President & COO Michael Meyers - Chief Medical Officer & Senior VP Peter Ordentlic...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...